Your browser doesn't support javascript.
loading
Long-term Survival and Prognostic Factors of Breast Cancer.
Olfatbakhsh, Asiie; Heidari, Leila; Omidi, Zahra; Hashemi, Esmat-O-Sadat; Ansari, Maryam; Mozaffarian, Samaneh; Haghighat, Shahpar.
Afiliación
  • Olfatbakhsh A; Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
  • Heidari L; Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
  • Omidi Z; Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
  • Hashemi EO; Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
  • Ansari M; Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
  • Mozaffarian S; Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
  • Haghighat S; Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
Arch Iran Med ; 25(9): 609-616, 2022 09 01.
Article en En | MEDLINE | ID: mdl-37543886
BACKGROUND: Breast cancer survival rate is an important index for assessment of treatment effect in reducing the mortality. Weaimed to determine the fifteen-year survival rate for breast cancer at a referral center in Iran and its correlated factors. METHODS: This survival study enrolled patients with breast cancer who referred to Motamed Cancer Institute (MCI) from 1998 to2016. The survival rate was calculated using the Kaplan-Meier method. The relationship of demographic, clinical and therapeuticfactors with overall survival (OS) was studied using Cox's proportional hazard model. RESULTS: Totally, 3443 patients were studied. Their mean age and follow-up period were 47.7 (±11.43) years and 61.66 (±52.1)months, respectively. The median follow-up time was 48.4 months (range: 1-413 months), 49.7% of the patients had high schoolor higher education, and 71.3% presented in the early stage of the disease. Death occurred in 505 (14.7%) of the patients. Theoverall 2-, 5-, 7-, 10- and 15-year survival rates were 93%, 82%, 78%, 74%, and 66%, respectively. Lymph node involvement(HR=2.07; 95% CI: 1.38-3.09), tumor size≥5 cm (HR=2.83; 95% CI: 1.59-2.04), being single/divorced/widowed (HR=1.65;95% CI: 1.13-2.4), and education level
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans País/Región como asunto: Asia Idioma: En Revista: Arch Iran Med Año: 2022 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Irán
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans País/Región como asunto: Asia Idioma: En Revista: Arch Iran Med Año: 2022 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Irán